Listed by the USPTO as PYLA, EVELYN Y
Tech Center 1600 • Art Units: 1600 1633 1651
This examiner grants 56% of resolved cases
PYLA, EVELYN Y is assigned to Tech Center 1600 and Art Unit 1600, with 566 resolved cases. The allowance rate is 55.8%, the interview lift is 47.1%, and the median time to allowance is 1321 days. The interview figure is a prominent feature of the profile and supports using examiner interviews as part of prosecution planning.
Nissan Chemical Corporation, Massachusetts Institute of Technology, and Korea Institute of Science and Technology are the leading companies. BAKER BOTTS L.L.P., CHRISTENSEN O'CONNOR JOHNSON KINDNESS PLLC, and Element IP, PLC are the leading firms. Practitioners should consider aligning technical explanations and claim amendments for interview discussion.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18689897 | ENGINEERED MUSCLE AND CENTRAL NERVOUS SYSTEM COMPOSITIONS | Non-Final OA | Massachusetts Institute of Technology |
| 17762396 | CELL CULTURING MATERIALS | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 18543705 | Regeneration of a Functional Pulmonary Vascular Bed | Final Rejection | The General Hospital Corporation |
| 17795915 | COMPOSITIONS FOR TRANSLATION AND METHODS OF USE THEREOF | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18622525 | COMPOSITIONS AND METHODS FOR REDUCED TOXICITY IN TRANSPLANTATION USING JANUS KINASE (JAK) INHIBITORS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18636926 | CELL CULTIVATION METHOD, CELL SUPPORT COMPOSITE PRODUCTION METHOD, CULTIVATED CELLS, AND CELL SUPPORT COMPOSITE | Non-Final OA | NIKKISO CO., LTD. |
| 18804707 | METHOD OF TREATMENT | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18609070 | Use of Short Chain Fatty Acids in Cancer Prevention | Final Rejection | Temple University-Of The Commonwealth System of Higher Education |
| 18582703 | 3D spheroid having uniform size and composition comprising neuron and astrocyte derived from Alzheimer's disease patients, method for producing thereof, and method and kit for screening drug using thereof | Non-Final OA | Industry-University Cooperation Foundation Hanyang University Erica Campus |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy55.8% of resolved applications examined by Evelyn Y Pyla were allowed (566 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +47.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Evelyn Y Pyla took 1,321 days on average from filing to allowance.
Evelyn Y Pyla examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
